Aggressive Multimodality Therapy for Stage III Esophageal Cancer: A Phase I/II Study
|
|
- Lucinda Snow
- 6 years ago
- Views:
Transcription
1 Aggressive Multimodality Therapy for Stage III Esophageal Cancer: A Phase I/II Study E. Pendleton Alexander, MD, Timothy Lipman, MD, John Harmon, MD, and Robert Wadleigh, MD Divisions of Cardiothoracic Surgery, Gastroenterology, General Surgery, and Medical Oncology, Washington, DC VAMC and George Washington University Medical Center, Washington, DC Background. Stage III advanced locoregional esophageal carcinoma is frequently unresectable and inconsistently represented in therapeutic trials of esophageal cancer. Methods. From 1992 to 1998, 34 of 131 total esophageal cancer patients were designated stage III (16 T3N1, 9 T4N0, 9 T4N1) and medically fit to enter a combined modality protocol with continuous infusion 5-fluorouracil (CI5-FU, 300 to 600 mg/m 2 /day), high-dose external beam irradiation (60 Gy), and interval esophagectomy. Staging before and after induction therapy included computed tomography, endoscopy, and endoscopic ultrasound. Results. Significant toxicity from induction therapy included death (5/34; 14.7%), pneumonitis (5/34; 14.7%), mucositis (13/34; 38%), and hand-foot syndrome (3/34; 8.8%). In addition to the five deaths, 11 patients did not proceed to operation because of development of esophagorespiratory fistula in 3, distant disease in 2, persistence of T4 stage in 2, progression of comorbidities in 2, and patient refusal in 2. There was a discrepancy between clinical complete response (ccr) at restaging 56% (19/34) and pathologic CR (pcr) noted at the time of operation (8/34; 23.5%). Complete resections were possible in 16 of 18 patients explored. Complications in 4 patients included: death (1), airway injury (1), chylothorax requiring reoperation (1), anastomotic leak (1), recurrent nerve injury with vocal cord paresis (2), and ascaris infection (1). Actuarial survival analysis using the Kaplan-Meier method and log-rank testing showed a 36-month survival of 20% for the group as a whole and 27% for patients restaged ccr (ccr vs PR, p ). Treatment failure is predominantly distant, with good local control in resected patients. N0 node status was strongly associated with survival (N0 vs N1 p ). There is a trend towards improved survival in the resected group (resected 22% vs nonresected 10% at 3 years, p 0.17). Conclusions. Response rates and survival are commensurate with multiple completed phase II and III trials. These are attained at a higher treatment-related mortality. T4 patients can be successfully resected in selected patients. Even in advanced disease, nodal status is a significant predictor of survival. (Ann Thorac Surg 2000;69:363 8) 2000 by The Society of Thoracic Surgeons Multiple phase II and several randomized trials have been completed demonstrating that neoadjuvant chemoradiotherapy for esophageal carcinoma can provide complete response rates (CR) of 20% to 40%, median survival of 16 to 24 months, and a therapy related mortality rate of 5% to 12%. These trials have entered patients from multiple stages, and have inconsistently included the various TNM subsets of stage III: T3N1, T4N0, and T4N1 [1 6]. T3N1 has been generally considered to be incurable by operation alone, and T4 lesions are generally considered to be inoperable [7, 8]. Advances in staging hold promise for the development of stage-specific therapy [9, 10]. With these considerations, we initiated a trial of aggressive therapy for advanced locoregional stage III esophageal carcinoma, with a regimen including higher Presented at the Forty-fifth Annual Meeting of the Southern Thoracic Surgical Association, Orlando, FL, Nov 12 14, Address reprint requests to Dr Alexander, Division of Cardiothoracic Surgery, George Washington University Medical Center, 50 Irving St, NW, Washington, DC 20422; epalexander@med.va.gov. than usual radiation dosages (60 Gy) and continuous infusion 5-fluorouracil (300 to 600 mg/m 2 /day) at radiosensitizing doses. The aim of this trial was to establish whether response rates, treatment-related mortality, and survival commensurate with previously reported experiences could be obtained in advanced locoregional disease, and whether resection could be offered to patients previously considered unresectable. This trial was designed to evaluate the premise that more intensive induction therapy may be more appropriate for lesions generally considered incurable or inoperative by employing a higher than usual target radiation dose along with a continuous infusion of the chemotherapeutic agent with the highest documented response rate for esophageal cancer [11, 12]. Patients and Methods Patient Population and Eligibility Out of a total of 131 patients seen from May 1992 to May 1998 at the Washington DC VAMC, 34 patients with 2000 by The Society of Thoracic Surgeons /00/$20.00 Published by Elsevier Science Inc PII S (99)
2 364 ALEXANDER ET AL Ann Thorac Surg STAGE III ESOPHAGEAL CANCER 2000;69:363 8 untreated advanced locoregional nonmetastatic esophageal carcinoma were designated stage III and medically fit to enter a multimodal protocol. Eligibility criteria included an Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate hematologic, renal, and hepatic function defined as a white blood cell count of more than /L, platelet count more than /L, creatinine level less than 2.0 mg/dl, and bilirubin level of 2.0 mg/dl or less. Pulmonary function testing, dobutamine thallium, and echocardiography were required to establish operative cardiopulmonary risk. Exclusion criteria included a tumor located within the first 4 cm of the esophagus and celiac node disease. All patients entered had bulky mid-thoracic lesions. The study was approved by the Human Studies Committee, and written informed consent was obtained from all participants. Evaluation and Staging Initial evaluation included a detailed history and physical examination, chest radiography, and computerized tomography (CT) of the lower neck, chest, and upper abdomen. Barium swallow, esophagoscopy with biopsy, and bronchoscopy were performed in all patients. Esophageal ultrasound (EUS) was performed in the last 29 consecutive patients. Intravascular ultrasound was used to confirm aortic invasion in 2 patients. The last 13 consecutive patients underwent staging thoracoscopy and laparoscopy. Care was taken to avoid systematic upstaging. Bronchoscopic evidence of invasion or infiltration was required rather than abutment or juxtaposition to define a primary tumor as T4 airway. Concurrence was generally required between EUS and CT. Bone and head CT scans were obtained as warranted by clinical suspicion of metastatic disease. Tumor stage was defined according to the classification of the American Joint Committee on Cancer (AJCC) [13]. Patient Characteristics Of the 34 patients enrolled, all were male (18 black and 16 white). Mean age was 63 years at diagnosis (range 45 to 78 years). All patients presented with dysphagia and weight loss (mean 12.6 kg, range 4 to 31 kg). All patients had a history of tobacco abuse, and 32 of 34 had history of ethanol abuse. Comorbidities, especially chronic lung disease and vascular disease, were common. Prior aerodigestive tract malignancies had occurred in 5 of 34 patients. In this atavistic population of esophageal carcinoma, histology was predominantly squamous, with only 3 of 34 having adenocarcinoma. Staging before initiaion of therapy was: 16 T3N1, 9 T4N0, and 9 T4N1. The designator T4 was given for airway invasion in 16 and aortic invasion in 2. After initial evaluation, 28 of 34 patients received a percutaneous endoscopic gastrostomy for nutritional support, and all patients received long-term central venous access. Chemoradiotherapy The target of radiotherapy was the macroscopic tumor and involved lymph nodes, if any, surrounded by at least 4-cm proximal and distal margins and a 2-cm radial margin. The target area was extended to the inferior cervical area in the case of tumors above the carina. The anatomical mediastinum and the celiac area were not routinely treated. Treatment portals consisted of anteroposterior, posteroanterior, and opposed lateral fields. The spinal cord was shielded after 40 Gy. The specified dose was delivered at the intersection of the central axis of the beams, according to international guidelines [14]. A total dose of 60 Gy in 1.8-Gy daily fractions, 5 days a week, was received by each patient completing therapy. Chemotherapy consisted of continuous infusion 5-fluorouracil (CI5FU) and ran concurrently for the duration of radiotherapy. CI5FU was selected because of its effectiveness as a radiation sensitizer and high documented response rate in esophageal cancer [11, 12]. Target dosage was changed over the course of the protocol in response to perceived efficacy and toxicity. Target dosage varied as follows: 6 patients, 300 mg/m 2 /day; 13 patients, 400 mg/m 2 /day; 8 patients, 500 mg/m 2 /day; and 7 patients, 600 mg/m 2 /day. Transient dosage adjustments including discontinuation were made in individual patients in response to toxicity. Toxicity was defined according to the Cancer and Leukemia Group B expanded common toxicity criteria. Restaging After induction therapy, all tumors were restaged with esophagoscopy and CT scan. Esophageal ultrasound was performed in 21 of 34 patients, and bronchoscopy selectively. Absence of tumor on restaging was designated a clinical complete response (ccr). Exploration was planned if a patient s overall condition was adequate and there was no evidence of unresectability at restaging. Surgery Resection was planned for 1 month after the conclusion of neoadjuvant therapy, but was commonly delayed to allow the patient to recover from induction treatment. Sixteen of the 18 patients explored underwent complete resection. Nine patients had transhiatal esophagectomies and 7 had a right thoracotomy. Operative approach was planned on the basis of preoperative staging with thoracotomy planned for most lesions initially staged T4. A trans-hiatal approach was used in selected T4 patients designated ccr after induction therapy. All resected patients had a cervical esophagastrostomy, pyloroplasty, and a feeding jejunostomy. The pathologic stage of the tumor was determined according to the classification of the AJCC. The absence of viable tumor in the resected specimen was designated a pathologic complete response (pcr). Follow-up Follow-up evaluation was performed at least every 3 months with repeat CT scanning, barium swallow, bronchoscopy, and endoscopy when appropriate. Treatment failure was defined by any morphologic evidence of tumor, and the pattern of failure, local, distant or both, was recorded regardless of whether the patient pro-
3 Ann Thorac Surg ALEXANDER ET AL 2000;69:363 8 STAGE III ESOPHAGEAL CANCER 365 ceeded to resection or not [15, 16]. All in-hospital deaths were included in the survival analysis, and all deaths were presumed to be secondary to esophageal cancer. Statistical Analysis Survival was measured from the date of diagnosis to the date of death or October 1, Actuarial survival was calculated using the Kaplan-Meier method and comparisons made using the log-rank test. Fisher s exact test was used to determine whether a relationship existed between two nominal variables. Analysis of variance (ANOVA) was used to test for a relationship among multiple variables. Results Chemoradiotherapy Toxicity Induction therapy was rigorous and toxic. Five of 34 patients (14.7%) died during induction therapy: 4 from pneumonitis and 1 from cytomegalovirus sepsis. Pneumonitis occurred in a total of 5 patients and occurred predominantly at CI5FU doses greater than 400 mg/m 2 / day. Analysis of age, tumor stage, and 5FU dose by ANOVA did not, however, identify any statistically significant association between these variables and the development of pneumonitis. Pneumonitis was not seen in patients receiving 300/m 2 /day. Anorexia and fatigue occurred in virtually all patients. Other complications requiring modifications in CI5FU dosing in individual patients included grade 2 mucositis in 9 of 34 (38%), and grade 3 mucositis in 5 of 34 (14.7%). There was grade 2 neutropenia and grade 3 neutropenia each in 8 of 34 patients (24%). Hand-foot syndrome occurred in 3 of 34 patients (9%). Chemoradiotherapy Response At restaging, there was no demonstrable tumor in 19 of 34 patients, for a clinical complete response (ccr) rate of 56%. A partial response (PR) was noted in 10 other patients, for a PR of 29.4%, but only 3 of these patients had actual downstaging. For the entire patient group, downstaging occurred in 22 of 34 (64.7%). Restaging bronchoscopy in the 16 T4 airway patients demonstrated no identifiable tumor in 11 patients. Relief of dysphagia occurred in many but not all patients with downstaging. For the group as a whole, 14 of 34 (41%) had relief of dysphagia after induction therapy. Responses to chemoradiotherapy were occasionally dramatic given the extent of the primary tumor (Fig 1). Fig 1. CT scans showing response to 60 Gy external beam irradiation and continuous-infusion 5-fluorouracil (400 mg/m 2 /day). (A) Initial staging, T4N0; (B) before surgical resection after completion of chemoradiotherapy, T0N0. Surgery Eighteen of 29 survivors of induction therapy underwent surgical exploration. Eleven patients did not proceed to operation because of development of distant disease in 2, development of tracheoesophegeal fistula in 3, persistence of T4 stage in 2, progression of comorbidities in 2, and patient refusal in 2. Two explored patients could not be resected because of T4 status identified intraoperatively. Complete resections were performed in 16 patients. Initial staging of these patients was T3N1 in 6, T4N0 in 6, and T4N1 in 4. Out of a total of 18 patients initially staged T4, including 14 with airway involvement, 10 resections were possible after induction therapy. Pathologic staging demonstrated no residual tumor in 8 patients, for a pcr of 8 of 34 (23.5%). This was substantially less than the ccr at restaging for all patients (56%), and the ccr at restaging before operation in patients resected (13/34; 38%). Progression of staging from protocol entry through treatment is summarized in Figure 2. Death resulted from resection in 1 patient, for an operative mortality rate of 6% (1/16). Combined with the deaths from induction therapy, this made the overall treatment mortality rate 17.6% (6/34). Other complications included airway injury (1), chylothorax requiring reoperation (1), anastomotic leak (1), recurrent nerve injury with vocal cord paresis (2), and ascaris infection (1). Survival At a median follow-up of 41 months, the actuarial survival for all patients entering the protocol at 12, 24, and 36 months was 58%, 28%, and 20%, respectively (Fig 3). Of all patients staged ccr, the 12-, 24-, and 36-month
4 366 ALEXANDER ET AL Ann Thorac Surg STAGE III ESOPHAGEAL CANCER 2000;69:363 8 Fig 2. Progression of staging in 34 patients with stage III esophageal carcinoma, including initial staging, restaging after neoadjuvant therapy, and staging at the time of exploration and/or resection. Thickness of lines corresponds to number of patients. actuarial survival was 69%, 48%, and 27%, respectively (Fig 4), and was significantly different from the group staged PR. There was a trend towards improved survival in the resected group versus the unresected group, but this failed to reach significance ( p 0.17) (Fig 5). Nodal status was a powerful predictor of survival, with a 57% survival at 36 months for N0 patients and 0% survival at 36 months for N1 patients. In spite of having large invasive bulky tumors, patients with an initial staging of T4N0 had a 12-, 24-, and 36-month actuarial survival of 89%, 77%, and 57%, respectively (Fig 6). Pattern of Failure For the group as a whole, locoregional control was good. Persistent or recurrent local disease was the first indicator of macroscopic treatment failure in 4 of 34 patients (12%). Distant treatment failure, occurring either as metastatic disease, or persistence or recurrence outside the radiation port, occurred in 12 of 34 (35%). Local and distant treatment failure were identified simultaneously in 3 of 34 patients (9%), making the total local failure rate 7 of 34 (20%) and the total distant failure rate 15 of 34 (44%). Treatment failure in resected patients was predominantly distant in 7 of 16 (41%), with simultaneous local and distant failure in 1 patient and local failure in 1 patient. Consequently, excellent locoregional control was obtained in 14 of 16 (87.5%) resected patients. Comment Aggressive therapy for this group of patients with advanced locoregional stage III esophageal cancer resulted in a ccr of 56% and a pcr of 23.5%, at the expense of a treatment related mortality rate of 17.6%. These response rates are similar but the mortality is higher in comparison with multiple completed trials [1 6]. Pneumonitis was the most significant contributing factor to this high mortality rate. Pneumonitis was not seen in patients treated at the lower level of CI5FU dosing (300 mg/m 2 /day). Fig 3. Actuarial survival for the group as a whole. Fig 4. Actuarial survival for patients restaged ccr and PR after chemoradiotherapy and including all subsequent treatment. The difference between the ccr group and the PR group was highly significant.
5 Ann Thorac Surg ALEXANDER ET AL 2000;69:363 8 STAGE III ESOPHAGEAL CANCER 367 Fig 5. Actuarial survival for resected and unresected patients. The difference approaches statistical significance. Whether a higher treatment mortality will continue to accompany aggressive multimodality treatment of advanced lesions will need to be established with further study. Selected T4 lesions can be successfully resected after aggressive induction therapy. Even in large, bulky, invasive lesions, nodal status remains a powerful determinant of survival, making accurate staging vital in planning therapy. One other published report supports an aggressive approach in patients with tracheobronchial involvement, with 9 of 23 patients successfully undergoing surgery after induction chemoradiotherapy [17]. Could the favorable results reported here in T4N0 patients have resulted from incorrectly staging lesions that were actually T3N0? Staging was performed with care to avoid upstaging. Multiple staging modalities were used but interpreted conservatively. Tracheoesophageal fistulae (TEF) developed in 3 patients all actually initially staged T3N1. Does aggressive therapy of airway involvement promote the development of TEF? In this series of patients, airway involvement was successfully treated in three times as many patients as those developing TEF. An aggressive approach appears warranted in T4NO patients, and operation should be considered in patients Fig 6. Actuarial survival for N0 and N1 patients within stage III. The difference between these groups was highly significant. with a dramatic response to induction therapy. This issue also awaits further study. The role of surgery in the multimodal therapy of esophageal cancer has been questioned. The wide discrepancy between clinical and pathologic staging seen in this study, and widely reported elsewhere [1, 2], commonly results from the inability to image or biopsy residual viable tumor in an esophagus with regenerated squamous epithelium and a small intramural deposit of tumor. Resection after ccr removes these foci when present, at least limiting the potential for locoregional recurrence. Locoregional control is excellent with resection in this series, and this is symptomatically very important to patients. The trend towards improved survival with resection in this series may become significant with longer follow-up, as resection may contribute to the development of the late plateau in actuarial survival curves. Does the absence of a broader chemotherapeutic regimen, including agents such as cisplatinum or taxol, hasten distant treatment failure? The distant treatment failure rate noted in this series is commensurate with those reported elsewhere [1 6, 15, 16]. The theoretic attractiveness of induction chemotherapy in killing micrometastatic disease has not been supported by a recently completed intergroup trial, which showed no advantage to neoadjuvant chemotherapy [18]. Until newer agents with novel actions are available, the principal value of chemotherapy may come from its radiosensitizing properties. In conclusion, response rates demonstrated in multiple completed trials are possible in advanced locoregional disease at a higher level of treatment mortality. T4 lesions can be downstaged and resected with long-term survival. Even in large, bulky, invasive lesions, nodal status is a critical determinant of survival. References 1. Ajani JA. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus. Chest 1998;113: Ilson DH, Bains M, Ginsberg RJ, Kelsen DP. Neoadjuvant therapy of esophageal cancer. Surg Oncol Clin North Am 1997;6: Nygaard K, Hagen S, Hansen HS, et al. Preoperative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of preoperative radiotherapy and chemotherapy. The second Scandinavian Trial in esophageal cancer. World J Surg 1992;16: Walsh TN, Noonal N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodality therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: Urba S, Orringer M, Turrisi A, et al. A randomized trial comparing transhiatal esophagecomy (THE) to preoperative concurrent chemoradiation (CT/XRT) followed by esophagectomy in locoregional esophageal carcinoma [Abstract]. Proc Am Soc Clin Oncol 1995;14:A Al-Sarraf M, Martz K, Herskovic A, et al. Superiority of chemoradiotherapy vs radiotherapy in patients with esophageal cancer: final report of an intergroup randomized and confirmed study [Abstract]. Proc Am Soc Clin Oncol 1996; 15:206.
6 368 ALEXANDER ET AL Ann Thorac Surg STAGE III ESOPHAGEAL CANCER 2000;69: Murray GF, Wilcox BR, Stared PIK. The assessment of operability of esophageal carcinoma. Ann Thorac Surg 1977; 23: Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma. I. A critical review of surgery. Br J Surg 1980;67: Krasna MJ, Reed C, Jaklitsch MT, et al. Thoracoscopic staging for esophageal cancer: a prospective, multiinstitutional trial. Ann Thorac Surg 1995;60: LoCicero J. Laparoscopy/thoracoscopy for staging. II. Pretherapy nodal evaluation in carcinoma of the esophagus. Semin Surg Oncol 1993;9: Wittes RE, Adrianza ME, Parsons R, et al. Compilation of phase II results with single antineoplastic agents. Cancer Treat Rep 1985;4: Ajani JA. Contribution of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol 1994;21: Beahrs OH, Heusen DE, Hutter RV, Myers MH, eds. Manual for staging cancer, 3rd ed. Philadelphia: Lippincott; 1988: Dose specification for reporting external beam therapy with photons and electrons. ICRU Report 29. Washington, DC: International Commission on Radiation Unit and Measurements, Aisner J, Forastiere A, Aroney R. Patterns of recurrence for cancer of the lung and esophagus. Cancer Treat Symp 1983;2: Sugimachi K, Inokuchi K, Kuwano H, Kai H, Okamura T, Okudaira Y. Patterns of recurrence after curative resection for carcinoma of the thoracic part of the esophagus. Surg Gynecol Obstet 1983;157: Sileni VC, Tomio L, Koussis H, et al. Concomitant radiotherapy and chemotherapy followed by surgery in esophageal carcinoma with bronchotracheal involvement [abstract]. Proc Am Soc Clin Oncol 1996;15: Kelsen DP, Ginsberg R, Qian C, et al. Chemotherapy followed by operation versus operation alone in the treatment of patients with localized esophageal cancer: a preliminary report of intergroup study 113 (RT0G 89-11) [Abstract]. Proc Am Soc Clin Oncol 1997;16:A276. DISCUSSION DR CHARLES L. WILLEKES (Muskegon, MI): That was an excellent paper. I enjoyed it very much. One question: did you notice any difference in the histological subtypes, squamous versus adenocarcinoma? And second of all, those patients who underwent complete resection, in regard to the number of nodes or the distance of the nodes from the primary tumor, were there any differences in outcome? DR ALEXANDER: There were only three adenocarcinomas in this series, and the adenocarcinomas that were stage T4 were T4 because of aortic invasion. We have seen one adenocarcinoma with airway invasion. In terms of numbers of lymph nodes and distant lymph nodes, an exclusion criterion for this protocol was celiac lymph node disease. In terms of numbers of lymph nodes, we did not use lymph node mapping, which I think everyone should, so our data are incomplete on that. I would tell you that my impression is that patients meeting the new N2 staging criterion for esophageal cancer do much worse, and, in general, lymphatic metastases appears to be a very powerful predictor of survival, as we showed, even in patients with huge primary tumors. I think it would be worse in patients with more extensive lymph adenopathy.
Although esophagectomy remains the standard of care for esophageal
Keresztes et al General Thoracic Surgery Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: Results of a phase II trial R. S. Keresztes, MD J. L. Port, MD M. W. Pasmantier,
More informationCHEMOTHERAPY FOLLOWED BY SURGERY VS. SURGERY ALONE FOR LOCALIZED ESOPHAGEAL CANCER
CHEMOTHERAPY FOLLOWED BY VS. ALONE FOR LOCALIZED ESOPHAGEAL CANCER CHEMOTHERAPY FOLLOWED BY COMPARED WITH ALONE FOR LOCALIZED ESOPHAGEAL CANCER DAVID P. KELSEN, M.D., ROBERT GINSBERG, M.D., THOMAS F. PAJAK,
More informationESOPHAGEAL CANCER. Dr. Paul Gardiner December 17, 2002 Discipline of Surgery Rounds
ESOPHAGEAL CANCER Dr. Paul Gardiner December 17, 2002 Discipline of Surgery Rounds ESOPHAGEAL CANCER I. EPIDEMIOLOGY INCIDENCE, DIAGNOSIS & STAGING II. TREATMENT OPTIONS Current role of induction therapies
More informationOverall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer
Original Article Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer Faisal A. Siddiqui 1, Katelyn M. Atkins 2, Brian S. Diggs 3, Charles R. Thomas Jr 1,
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 22 NOVEMBER 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Adjuvant Chemotherapy for Resected Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction, and Cardia:
More informationEsophageal cancer located at the cervical and upper thoracic
ORIGINAL ARTICLE Esophageal Cancer Located at the Neck and Upper Thorax Treated with Concurrent Chemoradiation: A Single- Institution Experience Shulian Wang, MD,* Zhongxing Liao, MD, Yuan Chen, MD, Joe
More informationSETTING Fudan University Shanghai Cancer Center. RESPONSIBLE PARTY Haiquan Chen MD.
OFFICIAL TITLE A Phase Ⅲ Study of Left Side Thoracotomy Approach (SweetProcedure) Versus Right Side Thoracotomy Plus Midline Laparotomy Approach (Ivor-Lewis Procedure) Esophagectomy in Middle or Lower
More informationControversies in management of squamous esophageal cancer
2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous
More informationCase Scenario year-old white male presented to personal physician with dyspepsia with reflux.
Case Scenario 1 57-year-old white male presented to personal physician with dyspepsia with reflux. 7/12 EGD: In the gastroesophageal junction we found an exophytic tumor. The tumor occupies approximately
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic cancer Section AA Cancer Centre Referrals In the absence of metastatic
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationCase Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.
Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationWHO BENEFITS FROM ADJUVANT CHEMOTHERAPY RADIATION CHEMORADIATION? Dr. Paul Gardiner April 23, 2001 Discipline of Surgery Grand Rounds
WHO BENEFITS FROM ADJUVANT CHEMOTHERAPY RADIATION CHEMORADIATION? Dr. Paul Gardiner April 23, 2001 Discipline of Surgery Grand Rounds LUNG Dr. Greenland ESOPHAGUS Dr. Gardiner ESOPHAGEAL CANCER 1200 new
More informationMinimally Invasive Esophagectomy- Valuable. Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006
Minimally Invasive Esophagectomy- Valuable Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006 Overview Esophageal carcinoma What is minimally invasive esophagectomy (MIE)?
More informationThe prognosis for patients with esophageal cancer is poor.
ORIGINAL ARTICLE A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal Cancer Henry Wang, MD, Janice Ryu, MD, David Gandara, MD, Richard J. Bold, MD, Shiro Urayama,
More informationShort-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer
Short-Course Induction Chemoradiotherapy With Paclitaxel for Stage III Non-Small-Cell Lung Cancer Thomas W. Rice, MD, David J. Adelstein, MD, Jay P. Ciezki, MD, Mark E. Becker, MD, Lisa A. Rybicki, MS,
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationEsophageal cancer: Biology, natural history, staging and therapeutic options
EGEUS 2nd Meeting Esophageal cancer: Biology, natural history, staging and therapeutic options Michael Bau Mortensen MD, Ph.D. Associate Professor of Surgery Centre for Surgical Ultrasound, Upper GI Section,
More informationMANAGEMENT OF CA HYPOPHARYNX
MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable
More informationORIGINAL ARTICLE. aggressive disease with a poor prognosis. Its incidence in the United States has been increasing;
Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is It Worthwhile? ORIGINAL ARTICLE Wael Z. Tamim, MD; Robert S. Davidson, MD; Robert M. Quinlan, MD; Michael A. O Shea, MB, BCh; Richard K. Orr, MD;
More informationAliu Sanni MD SUNY Downstate Medical Center August 16, 2012
Aliu Sanni MD SUNY Downstate Medical Center August 16, 2012 Case Presentation 60yr old AAF with PMH of CAD s/p PCI 1983, CVA, GERD, HTN presented with retrosternal chest pain on 06/12 Associated dysphagia
More information7/20/2017. Esophageal Cancer: A Less Common But Deadly Cancer. Objectives. Disclosure Statement NYNPA Conference October Saratoga New York
Esophageal Cancer: A Less Common But Deadly Cancer 2017 NYNPA Conference October 18-22 Saratoga New York Mary McGreal DNP, RN, ANP-C, CCRN, CMC, Adjunct Professor at Stony Brook University School of Nursing
More informationCT PET SCANNING for GIT Malignancies A clinician s perspective
CT PET SCANNING for GIT Malignancies A clinician s perspective Damon Bizos Head, Surgical Gastroenterology Charlotte Maxeke Johannesburg Academic Hospital Case presentation 54 year old with recent onset
More informationDoes the Timing of Esophagectomy After Chemoradiation Affect Outcome?
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationDetermining Resectability and Appropriate Surgery for Esophageal Cancer
Determining Resectability and Appropriate Surgery for Esophageal Cancer Peter Baik, DO, FACOS Thoracic Surgery Cancer Treatment Centers of America 1 Esophageal and Esophagogastric Junction Cancers Siewert
More informationAdenocarcinoma of the distal esophagus and gastroesophageal
Original Article A Phase II Trial of Induction Epirubicin, Oxaliplatin, and Fluorouracil, Followed by Surgery and Postoperative Concurrent Cisplatin and Fluorouracil Chemoradiotherapy in Patients with
More informationPlattenepithelkarzinom des Ösophagus, 1 st -line
Plattenepithelkarzinom des Ösophagus, 1 st -line AIO-STO-0309 An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationResearch and Reviews Journal of Medical and Clinical Oncology
Comparison and Prognostic Analysis of Elective Nodal Irradiation Using Definitive Radiotherapy versus Chemoradiotherapy for Treatment of Esophageal Cancer Keita M 1,2, Zhang Xueyuan 1, Deng Wenzhao 1,
More informationThe management of advanced supraglottic and
ORIGINAL ARTICLE ORGAN PRESERVATION FOR ADVANCED LARYNGEAL CARCINOMA Robert L. Foote, MD, 1 R. Tyler Foote, 1 Paul D. Brown, MD, 1 Yolanda I. Garces, MD, 1 Scott H. Okuno, MD, 2 Scott E. Strome, MD 3 1
More informationManagement of Esophageal Cancer: Evidence Based Review of Current Guidelines. Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center
Management of Esophageal Cancer: Evidence Based Review of Current Guidelines Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center Case Presentation 68 y/o male PMH: NIDDM, HTN, hyperlipidemia, CAD s/p stents,
More informationHong-Gyun Wu, M.D., Charn Il Park, M.D., S ung Whan Ha, M.D., and Il Han Kim, M.D.
J. Korean Soc Ther Radiol Oncol 1999;17(1):108 112 1) S ign ifica nce of S uprac lav ic ula r Lymph Node Invo lve me nt o n Dete rm inat io n of Clin ica l Stag ing fo r Tho rac ic Es o phagea l Ca rc
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationThe Role of Radiation Therapy in the Management of Esophageal Cancer
The Role of Radiation Therapy in the Management of Esophageal Cancer N. V. Raman, MD, and William Small, Jr, MD Radiation therapy plays an important role in the management of esophageal cancer. Background:
More informationRADIATION THERAPY WITH ONCE-WEEKLY GEMCITABINE IN PANCREATIC CANCER: CURRENT STATUS OF CLINICAL TRIALS
doi:10.1016/s0360-3016(03)00449-8 Int. J. Radiation Oncology Biol. Phys., Vol. 56, No. 4, Supplement, pp. 10 15, 2003 Copyright 2003 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/03/$
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationAccuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a national cancer database analysis
Review Article Accuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a national cancer database analysis Ravi Shridhar 1, Jamie Huston 2, Kenneth L. Meredith 2 1 Department of Radiation
More informationLya Crichlow, MD Kings County Hospital Center September 3, 2009 Morbidity and Mortality Conference Case presentation 56 year old male who presented with 1 week history of dysphagia Unable to tolerate solids
More informationEsophageal carcinomas in 2012 affected 17,460 Americans,
Original Article A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas Hoosier Oncology Group G05-92 Carlos R. Becerra, MD,*
More informationNewly Diagnosed Cases Cancer Related Death NCI 2006 Data
Multi-Disciplinary Management of Esophageal Cancer: Surgical and Medical Steps Forward Alarming Thoracic Twin Towers 200000 150000 UCSF UCD Thoracic Oncology Conference November 21, 2009 100000 50000 0
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationUtility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer
ORIGINAL ARTICLES: GENERAL THORACIC Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene M. Correa, PhD,
More informationQuiz Adenocarcinoma of the distal stomach has been increasing in the last 20 years. a. True b. False
Quiz 1 1. Which of the following are risk factors for esophagus cancer. a. Obesity b. Gastroesophageal reflux c. Smoking and Alcohol d. All of the above 2. Adenocarcinoma of the distal stomach has been
More informationRectal Cancer: Classic Hits
Rectal Cancer: Classic Hits Charles M. Friel, MD Associate Professor of Surgery Section of Colon and Rectal Surgery University of Virginia September 28, 2016 None Disclosures 1 Objectives Review the Classic
More informationDetermining the Optimal Surgical Approach to Esophageal Cancer
Determining the Optimal Surgical Approach to Esophageal Cancer Amit Bhargava, MD Attending Thoracic Surgeon Department of Cardiovascular and Thoracic Surgery Open Esophagectomy versus Minimally Invasive
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationPneumonectomy After Induction Rx: Is it Safe?
Pneumonectomy After Induction Rx: Is it Safe? David J. Sugarbaker, M.D. Director, Chief, Division of Thoracic Surgery The Olga Keith Weiss Chair of Surgery of Medicine at, Pneumonectomy after induction
More informationThe Learning Curve for Minimally Invasive Esophagectomy
The Learning Curve for Minimally Invasive Esophagectomy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J Swanson, M.D. Professor of Surgery Harvard
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationCase presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery
More informationSingle centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer
Original Article Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer Ben Alexander Fulton 1, Joanna Gray 2, Alexander McDonald
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationAdenocarcinoma of gastro-esophageal junction - Case report
Case Report denocarcinoma of gastro-esophageal junction - Case report nupsingh Dhakre 1*, Ibethoi Yengkhom 2, Harshin Nagori 1, nup Kurele 1, Shreedevi. Patel 3 1 2 nd year Resident, 2 3rd year Resident,
More informationORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER
ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER Vasu Divi, MD, 1 * Francis P. Worden, MD, 1,2 * Mark E. Prince, MD, 1 Avraham Eisbruch, MD, 3 Julia S. Lee, MD, 4
More informationClinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma: is there really a difference?
Diseases of the Esophagus (2008) 21, 596 600 DOI: 10.1111/j.1442-2050.2008.00817.x Original article Clinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma:
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationA Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationTitle. CitationInternational Journal of Clinical Oncology, 20(6): 1. Issue Date Doc URL. Rights. Type. File Information
Title Clinical outcomes of weekly cisplatin chemoradiother Sakashita, Tomohiro; Homma, Akihiro; Hatakeyama, Hir Author(s) Takatsugu; Iizuka, Satoshi; Onimaru, Rikiya; Tsuchiy CitationInternational Journal
More informationImpact of esophageal cancer staging on overall survival and disease-free survival based on the 2010 AJCC classification by lymph nodes
Journal of Radiation Research, 2013, 54, 307 314 doi: 10.1093/jrr/rrs096 Advance Access Publication 2 November 2012 Impact of esophageal cancer staging on overall survival and disease-free survival based
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationAppendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer
Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer Locoregional (N stage) disease was redefined in the seventh edition of the AJCC Cancer Staging Manual as any periesophageal lymph
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationGTS. The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 3 605
Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders Robert J. Cerfolio, MD, FACS,
More informationTowards a more personalized approach in the treatment of esophageal cancer focusing on predictive factors in response to chemoradiation Wang, Da
University of Groningen Towards a more personalized approach in the treatment of esophageal cancer focusing on predictive factors in response to chemoradiation Wang, Da IMPORTANT NOTE: You are advised
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationRadiation Therapy for Recurrent Esophageal Cancer after Surgery: Clinical Results and Prognostic Factors
Radiation Therapy for Recurrent Esophageal Cancer after Surgery: Clinical Results and Prognostic Factors Yoshiyuki Shioyama 1, Katsumasa Nakamura 1, Saiji Ohga 1, Satoshi Nomoto 1, Tomonari Sasaki 1, Toshihiro
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationA COMPARISON OF MULTIMODAL THERAPY AND SURGERY FOR ESOPHAGEAL ADENOCARCINOMA. Patients. The New England Journal of Medicine
A COMPARISON OF MULTIMODAL THERAPY AND SURGERY FOR ESOPHAGEAL ADENOCARCINOMA THOMAS N. WALSH, M.D., NOIRIN NOONAN, M.B., DONAL HOLLYWOOD, PH.D., ALAN KELLY, PH.D., C.STAT., NAPOLEON KEELING, M.D., AND
More informationCharacteristics of intramural metastasis in gastric cancer. Tatsuya Hashimoto Kuniyoshi Arai Yuichi Yamashita Yoshiaki Iwasaki Tsunekazu
ORIGINAL ARTICLE Characteristics of intramural metastasis in gastric cancer Tatsuya Hashimoto Kuniyoshi Arai Yuichi Yamashita Yoshiaki Iwasaki Tsunekazu Hishima Author for correspondence: T. Hashimoto
More informationCis-diammine-glycolatoplatinum (Nedaplatin) and
å ORIGINAL ARTICLE D A NewCombination Chemotherapy with Cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for Advanced Esophageal Cancers Takashi Yoshioka, Makio Gamoh, Ryusaburo Shineha*,
More informationL impatto dell imaging sulla definizione della strategia terapeutica
GISCoR L impatto dell imaging sulla definizione della strategia terapeutica M. Galeandro U.C. Radioterapia Oncologica ASMN-IRCCS Reggio Emilia 14 Novembre 2014 Rectal Cancer TNM AJCC-7 th edition 2010
More informationORIGINAL ARTICLE. Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck for Organ Preservation and Palliation
ORIGINAL ARTICLE Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck for Organ Preservation and Palliation Michael E. Poole, PA-C, MPH; Scott L. Sailer, MD; Julian G. Rosenman,
More informationEsophageal cancer is a significant health hazard for
Postoperative Radiotherapy Improved Survival of Poor Prognostic Squamous Cell Carcinoma Esophagus GENERAL THORACIC Junqiang Chen, MD, Ji Zhu, MD, Jianji Pan, MD, Kunshou Zhu, MD, Xiongwei Zheng, MD, Mingqiang
More informationExercise 15: CSv2 Data Item Coding Instructions ANSWERS
Exercise 15: CSv2 Data Item Coding Instructions ANSWERS CS Tumor Size Tumor size is the diameter of the tumor, not the depth or thickness of the tumor. Chest x-ray shows 3.5 cm mass; the pathology report
More informationHong Kong Society of Upper Gastrointestinal Surgeons CLINICAL MEETING 29 NOV 2012
Hong Kong Society of Upper Gastrointestinal Surgeons CLINICAL MEETING 29 NOV 2012 Esophageal Leiomyoma Introduction Case presentation Operative video Discussion Esophageal Leiomyoma Benign tumors of the
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationAytul OZGEN 1, *, Mutlu HAYRAN 2 and Fatih KAHRAMAN 3 INTRODUCTION
Journal of Radiation Research, 2012, 53, 916 922 doi: 10.1093/jrr/rrs056 Advance Access Publication 21 August 2012 Mean esophageal radiation dose is predictive of the grade of acute esophagitis in lung
More informationUpper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012
Upper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012 Version Control This is a controlled document please destroy all previous versions on receipt
More informationManagement of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting
More informationPREOPERATIVE CHEMOTHERAPY VERSUS SURGICAL THERAPY ALONE FOR SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS: A PROSPECTIVE RANDOMIZED TRIAL
PREOPERATIVE CHEMOTHERAPY VERSUS SURGICAL THERAPY ALONE FOR SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS: A PROSPECTIVE RANDOMIZED TRIAL Simon Law, MB, BChir, FRCSEd Manson Fok, MB, BS, FRCSEd Selwyn Chow*
More informationCase Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
More informationAbstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 Final Pathology:
Abstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 A 74 year old male with a history of GERD presents complaining of dysphagia. An esophagogastroduodenoscopy
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationdoi: /theoncologist
Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches Mary Koshy, Natia Esiashvilli, Jerome C. Landry, Charles R. Thomas, Jr. and Richard H. Matthews The Oncologist
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationLong-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial
Liu et al. Radiation Oncology 2012, 7:142 RESEARCH Open Access Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial
More information